Revenio Group Corporation: Notice pursuant to chapter 9, section 5 of the securities market act

Revenio Group Corporation, Stock Exchange Release, October 14, 2020 at 21.45

Notice pursuant to chapter 9, section 5 of the securities market act

Revenio Group Corporation has October 13, 2020 received a notification of change in holdings in accordance with Chapter 9, Section 5 of the Securities Markets Act that The Capital Group Companies Inc’s share of the total number of shares and voting rights in Revenio Group Corporation has decreased to less than five per cent.

The Capital Group Companies Inc now holds 1.288.756 shares in Revenio Group Corporation, which is 4.8399 per cent of the company's shares and voting rights.

The total number of Revenio Group Corporation's shares recorded in the trade register is 26.627.557.

Revenio Group Corporation

For further information, please contact:

CFO Robin Pulkkinen, tel.  +358 50 505 9932
robin.pulkkinen@revenio.fi
www.revenio.fi

DISTRIBUTION:

Nasdaq Helsinki Ltd

Financial Supervisory Authority

Main media

www.revenio.fi

Revenio Group in brief

Revenio, a health technology group operating in the international markets, is one of the global leaders in ophthalmic appliances. Revenio Group's ophthalmic diagnostic solutions include intraocular pressure measurement devices under the Icare brand and retinal imaging devices. The main tool for the detection and diagnosis of glaucoma and its monitoring during treatment are intraocular pressure measurement (tonometry), retinal imaging, and visual field tests (perimetry).

The Revenio Group consists of Icare Finland Oy, Icare USA Inc., Revenio Italy S.R.L, CenterVue SpA, Revenio Research Oy, Done Medical Oy and Oscare Medical Oy.

The common denominators of Revenio's business operations include patient-oriented screening, follow-up and the global need to make cost savings through preventive health care. Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The aim is to improve the quality of life through health technology solutions which enable more effective diagnostics. Revenio Group’s focus is on the early detection of glaucoma, diabetic retinopathy and macular degeneration, and the monitoring of these during the treatment process. Revenio Research concentrates on the commercialization of systems supporting the diagnosis of and treatment planning for skin cancer and asthma.

In 2019, Revenio Group's net sales totalled EUR 49.5 million, with its net operating profit standing at 25.5 %. Revenio Group Corporation is listed on Nasdaq Helsinki.


Subscribe